EMV Capital (AIM:EMVC) has hailed the acquisition of intellectual property and clinical assets from the collapsed biotechnology company Destiny Pharma as a 'meaningful opportunity' to generate shareholder value.
The investment group, which focuses on deep tech and life sciences, struck a deal earlier this month to buy the assets for up to £2.5 million and raised about £1.3 million from investors to fund the purchase and working capital.
Dr Ilian Iliev, chief executive of EMV Capital, said: “Our Venture Building programme is progressing a core group of companies through key milestones, with strong prospects for significant potential capital returns.
"The exciting IP and clinical assets recently acquired from Destiny Pharma offer a meaningful opportunity to generate further shareholder value.”
The update came as the group reported a slight fall in revenue to £1.1 million for the first half of 2025, compared with £1.2 million a year earlier. Losses narrowed to £1.5 million from £1.8 million.
Net assets eased to £13.6 million, down from £14.1 million at the end of 2024, though total assets rose to £19.7 million.
Assets under management stood at £104.7 million, a shade lower than the £106.7 million recorded in the same period last year, but still sharply higher than the £12 million the group managed when it adopted its current strategy five years ago.
EMV Capital now has stakes in more than 70 portfolio companies across life sciences, technology and sustainability.
The firm’s Martlet Capital arm recently achieved a 2.5 times return on a healthcare investment following a secondary sale, while a new co-investment into plant polymers business Xampla underscored its ability to expand fundraising efforts across its network.
Iliev said the company’s mix of fund management, corporate finance and advisory work provided resilience despite tough market conditions, with a continued focus on supporting portfolio companies and expanding its funds practice.